Are there predictors of Remicade treatment success or failure

摘要: Infliximab (Remicade®) is an antitumor necrosis factor (TNF) therapy effective in both induction and maintenance of remission Crohn's disease. Identifying predictors response or relapse to infliximab important given the potential toxicities cost this therapy. Currently available data suggest that concurrent immunosuppressant therapy, certain clinical characteristics, biological immunological markers, gene polymorphism may correlate with infliximab. However, no single variable has been consistently shown definitely proven studies be a predictor practical value current practice. Data from literature these areas are reviewed article, pointing need for additional research topic.